FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Panel Votes Down Pacira sNDA for Pain Blocker

FDAs Anesthetic and Analgesic Drug Products Advisory Committee votes 6 to 4 to not recommend approval of a Pacira Pharmaceuticals supplemental NDA for...

Federal Register

Public Meeting on Pediatric Device Development

Federal Register notice: FDA announces an 8/13-14 public meeting entitled Pediatric Medical Device Development.

Federal Register

Guide on How to Prepare Combination Product Designation Request

Federal Register notice: FDA makes available a guidance entitled How to Prepare a Pre-Request for Designation (Pre-RFD).

Human Drugs

FDA Approves AstraZenecas Imfinzi in Lung Cancer

FDA approves AstraZenecas Imfinzi (durvalumab) for treating patients with Stage III non-small cell lung cancer whose tumors are not able to be surgica...

Human Drugs

FDA Mulls European Drug Supplies for Generic Testing: Gottlieb

As a means to help bring down rising drug costs, FDA commissioner Scott Gottlieb says the agency is exploring how to allow generic drug firm to acquir...

Medical Devices

NEJM Perspective Breaks Down Real World Evidence for Devices

Two medical device researchers outline benefits and pitfalls of FDA relying on real world evidence in their regulatory decision making.

Federal Register

Lotensin HCT Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that U.S. Pharmaceutical Holdings Lotensin HCT (benazepril hydrochloride; hydrochlorothiazide) oral tablets, 5...

Federal Register

Draft Guide on eSubmission Data for BIMO Inspection Prep

Federal Register notice: FDA makes available a draft guidance entitled Standardized Format for Electronic Submission of NDA and BLA Content for the Pl...

Federal Register

Panel to Review Akcea Therapeutics NDA in May

Federal Register notice: FDA announces a 5/10 Endocrinologic and Metabolic Drugs Advisory Committee meeting to review Akcea Therapeutics NDA.

Human Drugs

5 Neurological Treatment Guidances Out

FDA releases five guidances, developed through a new, streamlined process, to speed development of treatments for several neurological conditions.